What question did this study set out to answer?

To evaluate the safety and effectiveness of zoldonrasib in patients with KRAS G12D-mutant non-small cell lung cancer.

April 21, 2026

Zoldonrasib Deemed Safe, Effective in KRAS G12D-mutant NSCLC

Key Points

To evaluate the safety and effectiveness of zoldonrasib in patients with KRAS G12D-mutant non-small cell lung cancer.
Conducted a phase I clinical trial
Administered zoldonrasib to patients with KRAS G12D mutations
Monitored objective response and survival rates
Achieved an objective response rate of 52%
Reported a disease control rate of 93%
Showed median progression-free survival of 11.1 months and 73% overall survival at 12 months

Abstract

Abstract: In updated phase I clinical trial results, patients treated with zoldonrasib, a KRASG12D-selective inhibitor under study in non–small cell lung cancer, showed an objective response rate of 52%, a disease control rate of 93%, a median progression-free survival of 11.1 months, and a 73% overall survival at 12 months.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Journals

Cancer Discovery

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Zoldonrasib Deemed Safe, Effective in KRAS G12D-mutant NSCLC

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Journals

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Also consider